ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

PHASE3CompletedINTERVENTIONAL
Enrollment

3,858

Participants

Timeline

Start Date

January 31, 1996

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Breast Cancer
Interventions
DRUG

Tamoxifen

DRUG

Anastrozole

Trial Locations (52)

Unknown

Research Site, Amstetten

Research Site, Bad Ischl

Research Site, Baden

Research Site, Bregenz

Research Site, Bruck/Mur

Research Site, Dornbirn

Research Site, Eisenstadt

Research Site, Feldbach

Research Site, Feldkirch

Research Site, Freistadt

Research Site, Fürstenfeld

Research Site, Gmünd

Research Sites, Graz

Research Site, Güssing

Research Site, Hainburg an der Donau

Research Site, Hartberg

Research Site, Hollabrunn

Research Site, Horn

Research Site, Innsbruck

Research Site, Judenburg

Research Site, Kirchdorf

Research Site, Klagenfurt

Research Sites, Klosterneuburg

Research Site, Kufstein

Research Site, Leoben

Research Sites, Linz

Research SIte, Melk

Research Site, Mistelbach

Research Site, Mödling

Research Site, Neunkirchen

Research Site, Oberpullendorf

Research Site, Oberwart

Research Site, Ried im Innkreis

Research Site, Rohrbach

Research Site, Rottenmann

Research Site, Saint Poelton

Research Site, Saint Veit/Glan

Research Site, Salzburg

Research Site, Schärding

Research Site, Scheibbs

Research Site, Schladming

Research Site, Schwarzach/Pongau

Research Site, Spittal/Drau

Research Site, Steyr

Research Site, Tulln

Research Sites, Vienna

Research Site, Villach

Research Site, Vöcklabruck

Research Site, Waidhofen/Thaya

Research Site, Wels

Research Site, Wolfsberg

Research Site, Zams

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY